NRG-HN001. Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Mitchel Fromm, MD
McDowell Cancer Research at 330-344-6348
Cleveland Clinic Akron General 1 Akron General Avenue Akron, OH 44307 330.344.6000 1.800.221.4601 © 2017 Cleveland Clinic Akron General
This site complies with the HONcode standard for trustworthy health information: verify here.